Abstract 88P
Background
Clinical trials (CTs) play a crucial role in developing new cancer treatments and enhancing patient outcomes. However, participation in these trials remains low across middle east and north Africa region(MENA). This study aims to evaluate the knowledge and attitudes of the general population regarding cancer clinical trials across multiple MENA countries.
Methods
A multicenter cross-sectional study was conducted between March and May 2024, involving 5,422 participants from the general population in the MENA region. Data was collected using a standard population-based cross-sectional survey, and was distributed both online and in-person. Convenience sampling was employed, and participants were included based on their ability to read and willingness to complete the survey. Data analysis was conducted using Jamovi 2.3.28 software.
Results
Of the 5,422 responses, significant participation was observed from Egypt (22.9%) and Bahrain (20.9%). Knowledge of CTs was moderate overall, with 63.5% of participants being familiar with the concept; however, only 9.1% exhibited a high level of knowledge. Attitudes toward CT participation was largely negative, with 83.8% of respondents expressing reluctance to participate, despite 77.6% indicating an interest in receiving more information about CTs. Knowledge scores were significantly associated with demographic factors, including occupation and education (p < 0.001). Multinomial logistic regression indicated that private and governmental employees had higher knowledge levels compared to unemployed individuals. Participants with chronic illnesses and those with prior research participation also demonstrated greater knowledge. Attitude scores, on the other hand, were significantly correlated with age and gender (p < 0.003).
Conclusions
The findings of this study underscore the need for targeted educational interventions and public awareness campaigns to improve knowledge about CTs and foster a more positive attitude towards participation. Addressing these barriers is critical for increasing regional engagement in clinical research, enhancing the development of tailored cancer therapies, and improving patient outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.